Action Alpha Tau Medical - DRTS

Alpha Tau Medical Ltd (DRTS) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

10,15

( 1,20% )

Prix Achat

10,13

Prix Vente

10,16

Volume échangé

351 830

9,47 Fourchette du Jour 10,1592

2,85 Plage de 52 semaines 11,62

Cap du marché

915,287M

Clôture Veille

10,03

Ouverture

9,47

Dernière Transaction

100

10.15

Dernière heure de transaction

19:18:58

Volume financier

US$ 3 436 436

VWAP

9,7673

Volume moyen (3 m)

US$ 700 711

Actions en circulation

90 176 067

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-14,68

Bénéfice par action (BPA)

-0,67

Chiffre d'affairess (LTM)

Bénéfice net (LTM)

-56,88M

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprisi... Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel. Show more

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.alphatau.com

Siège social

Jerusalem, Israel

Fondé

Alpha Tau Medical Ltd est coté dans le secteur Healthcare de la NASDAQ avec le ticker DRTS. Le dernier cours de clôture d'Alpha Tau Medical était de US$10,03. Au cours de la dernière année, les actions de Alpha Tau Medical ont été négociées dans une fourchette de prix de US$ 2,85 à US$ 11,62.

Alpha Tau Medical compte actuellement 90 176 067 actions en circulation. La capitalisation boursière d'Alpha Tau Medical est de US$915,29 million. Alpha Tau Medical a un ratio cours/bénéfice (ratio PE) de -14.68.

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in...

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients...

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s...

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive...

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local...

Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ:...

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete...

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the...

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the...

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

First patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.56	5.83941605839	9.59	10.2	9.21	498607	9.73029045	CS
4	-0.07	-0.684931506849	10.22	11.33	8.75	981740	9.93803053	CS
12	3.36	49.4845360825	6.79	11.62	6.7	757036	9.50486676	CS
26	5.05	99.0196078431	5.1	11.62	4.75	529876	8.67859707	CS
52	7.22	246.416382253	2.93	11.62	2.85	300103	8.05722428	CS
156	6.02	145.762711864	4.13	11.62	1.75	131038	6.90326011	CS
260	-1.4	-12.1212121212	11.55	20.65	1.75	138559	8.15174013	CS

DRTS - Frequently Asked Questions (FAQ)

What is the current Alpha Tau Medical Ltd share price?

The current share price of Alpha Tau Medical Ltd is US$ 10,15

How many Alpha Tau Medical Ltd shares are in issue?

Alpha Tau Medical Ltd has 90 176 067 shares in issue

What is the market cap of Alpha Tau Medical Ltd?

The market capitalisation of Alpha Tau Medical Ltd is USD 915,29M

What is the 1 year trading range for Alpha Tau Medical Ltd share price?

Alpha Tau Medical Ltd has traded in the range of US$ 2,85 to US$ 11,62 during the past year

What is the PE ratio of Alpha Tau Medical Ltd?

The price to earnings ratio of Alpha Tau Medical Ltd is -14,68

What is the registered address of Alpha Tau Medical Ltd?

The registered address for Alpha Tau Medical Ltd is Kiryat HaMada St. 5, Jerusalem, 9777605

What is the Alpha Tau Medical Ltd website address?

The website address for Alpha Tau Medical Ltd is www.alphatau.com

Which industry sector does Alpha Tau Medical Ltd operate in?

Alpha Tau Medical Ltd operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Alpha Tau Medical Ltd (DRTS)

Alpha Tau Medical Ltd (DRTS) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Alpha Tau Medical Ltd

DRTS Dernières nouvelles

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas Institute

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau to Participate in May Investor Conferences

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

DRTS - Frequently Asked Questions (FAQ)

DRTS Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités